Compare Sanofi SA (SNY) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs NEOS S&P 500 High Income ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while NEOS S&P 500 High Income ETF trades at $52.95. The key difference: Sanofi SA pays a 5.5% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | SPYI | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $54.07 |
52-Week Low | $41.33 | $47.98 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
SPYI (NEOS S&P 500 High Income ETF) trades at $53.01, down 0.11% with a bearish technical signal. The fund has grown to over $10 billion in assets under management and delivers consistent monthly distributions through its covered call strategy. Recent performance shows 8% year-to-date and 19% one-year returns, though trailing the broader S&P 500. The ETF's two-leg options strategy enables robust income generation while retaining partial upside exposure.
SPYI offers investors high-yield income with downside protection, making it attractive for retirement portfolios. However, the fund's 0.68% expense ratio and potential return of capital distributions require careful consideration. Market volatility benefits the options strategy, but sustained bull markets may limit upside participation compared to traditional index funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
